Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25657687 | 0.92 | KMT2A (0.48) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL23137983 | 0.91 | FABP5 (0.43) | KMT2AFABP7FABP5EPHX2MDM4 | |
| SCHEMBL25439639 | 0.91 | KMT2A (0.44) | KMT2AFABP7FABP5EPHX2MDM4 | |
| SCHEMBL17751716 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL13254138 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL17751637 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL17751714 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL17751719 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL17751718 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 | |
| SCHEMBL17751724 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| US-10011637-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170129925-A1 | PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISYS | SYNERGY PHARMACEUTICALS INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9580471-B2 | Process of preparing guanylate cyclase C agonists | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160145307-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2016-05-26 | — | — | US | disclosed |
| US-20160145307-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2016-05-26 | — | — | US | disclosed |
| US-20140155575-A1 | Process of Preparing Guanylate Cyclase C Agonists | SYNERGY PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155575-A1 | Process of Preparing Guanylate Cyclase C Agonists | SYNERGY PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20070134259-A1 | Methods and compositions for pharmacologially controlled targeted immunotherapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155575-A1 | Process of Preparing Guanylate Cyclase C Agonists | GUCY1A1, GUCY1B1, GUCY1A2 | KMT2A 3809/4885FABP7 2659/4885FABP5 3924/4885 |
| US-20070134259-A1 | Methods and compositions for pharmacologially controlled targeted immunotherapy | HAVCR2, FCGR3B, CD47 | KMT2A 1689/4885FABP7 1250/4885FABP5 1108/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | KMT2A 3991/4885FABP7 2527/4885FABP5 3373/4885 |
| US-20160145307-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | KMT2A 3991/4885FABP7 2527/4885FABP5 3373/4885 |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | KMT2A 3727/4885FABP7 1329/4885FABP5 2084/4885 |
| US-20170129925-A1 | PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISYS | GUCY1B1, GUCY1A1, GMPS | KMT2A 3979/4885FABP7 2378/4885FABP5 3770/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | KMT2A 3991/4885FABP7 2527/4885FABP5 3373/4885 |
| US-10011637-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | KMT2A 3991/4885FABP7 2527/4885FABP5 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.